ALATROFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H25F3N6O5
Molecular Weight	558.5091
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]1[C@H]2CN(C[C@@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=C(F)C=C(F)C=C5)C(O)=O

InChI

InChIKey=UUZPPAMZDFLUHD-VUJLHGSVSA-N

InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_Pharmacology
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/trovan.html

Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Plasmodium falciparum 75 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878530	Inhibitor 8504
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8504
Moraxella catarrhalis 10 Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8504
Staphylococcus aureus 70 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20407243	Inhibitor 8504
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Nosocomial pneumonia 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Pneumonia 91 Sources: https://www.drugs.com/pro/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Intra-abdominal infections 50 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Complicated skin and skin structure infections 11 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Pneumonia 91 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Complicated intra-abdominal infections 20 Sources: https://www.drugs.com/pro/trovan.html#Indications_And_Usage	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Gynecologic infections 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Skin infections 59 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997

C_max

Value	Dose	Analyte	Population
1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
4.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
9.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.6 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
32.2 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
46.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
46.3 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
20.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
22% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
28.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Vomiting (1 patient) Lightheadedness (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (11 patient) CNS disorder (NOS) (4 patients) Dizziness (2 patients) Dermatitis (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

AEs

AE	Significance	Dose	Population
Vomiting	1 patient	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Lightheadedness	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Nausea	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Gastrointestinal disorder NOS	11 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dermatitis	2 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dizziness	2 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
CNS disorder (NOS)	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741	UGT 219 sulfotransferases 39

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23401306/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes
sulfotransferases 39	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes

Sourcing

Vendor/Aggregator	ID	URL
AHH Chemical co.,ltd	MB-18104	http://www.ahhchemical.com/product/MB-18104.html
AK Scientific, Inc. (AKSCI)	X2115	http://www.aksci.com/item_detail.php?cat=X2115
Alfa Chemistry	146961-76-4	https://www.alfa-chemistry.com/alatrofloxacin-cas-146961-76-4-item-290329.htm
BioSynth	J-008289	https://www.biosynth.com/en/products/all-products/products/J-008289.html
BOC Sciences	146961-76-4	https://www.bocsci.com/l-alaninamide-l-alanyl-n-1a-5a-6a-3-6-carboxy-8-2-4-difluorophenyl-3-fluoro-5-8-dihydro-5-oxo-1-8-naphthyridin-2-yl-3-azabicyclo-3-1-0-hex-6-yl-cas-146961-76-4-item-166826.html
ChemMol	99045884	http://www.chemmol.com/chemmol/99045884.html
eNovation Chemicals	D674817	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674817
Lab Network	LN01284338	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01284338
MuseChem	M093915	https://www.musechem.com/product/M093915.html
Smolecule	S517830	http://www.smolecule.com/products/s517830
THE BioTek	bt-259048	https://www.thebiotek.com/product/inhibitors/bt-259048
ChEBI	CHEBI:9763	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9763
MolPort	MolPort-018-615-902	https://www.molport.com/shop/molecule-link/MolPort-018-615-902
ZINC	ZINC000100030989	http://zinc15.docking.org/substances/ZINC000100030989

PubMed

Title	Date	PubMed
The 2-pyridone antibacterial agents: 8-position modifications.	1999 Jul	10438895
Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin.	1999 Jul	10390245
Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated Chlamydial urethritis and cervicitis. Trovafloxacin Chlamydial Urethritis/Cervicitis Study Group.	1999 Oct	10534208
Trovafloxacin-induced acute hepatitis.	2000 Feb	10671353
Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro.	2000 Jun	10822086
Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.	2000 May	10832955
Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.	2000 May	10809347
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.	2000 Oct	10991859
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	2000 Oct	10991858
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.	2000 Sep	10952620
Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico.	2001	11760159
Bactericidal assays for fluoroquinolones.	2001	11089231
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.	2001 Dec	11837640
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.	2001 Dec	11786655
Quinolones and false-positive urine screening for opiates by immunoassay technology.	2001 Dec 26	11754677
Guidelines and critical pathways for severe hospital-acquired pneumonia.	2001 Feb	11171778
Use of broad spectrum antibiotics in six non-university Swiss hospitals.	2001 Jul 28	11582634
Experimental intravitreal application of trovafloxacin in rabbits.	2001 Jul-Aug	11464076
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.	2001 Jun	11442564
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001 Jun	11397615
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001 Jun	11389122
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001 May-Jun	11448561
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.	2001 Nov	11885973
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.	2001 Oct	11581436
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.	2001 Sep	11673035
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.	2002 Feb	11892894
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.	2002 Jan	11821174
Bactericidal mechanism of gatifloxacin compared with other quinolones.	2002 Jan	11751786
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.	2002 Jan	11751769
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.	2003 Feb	12696183
Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.	2009	19898647
Post-approval translational research itself has diverse ethics.	2010 Aug	20694908
Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction.	2010 Oct 6	20655887

Patents

Sample Use Guides

In Vivo Use Guide

Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days

Route of Administration: Other

In Vitro Use Guide

Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L

Name

Type

Language

ALATROFLOXACIN [VANDF]

Preferred Name

English

ALATROFLOXACIN

Official Name

English

Alatrofloxacin [WHO-DD]

Common Name

English

alatrofloxacin [INN]

Common Name

English

7-((1R,5S,6S)-6-((S)-2-((S)-2-AMINOPROPIONAMIDO)PROPIONAMIDO)-3-AZABICYCLO(3.1.0)HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C795